ImmunityBio (NASDAQ:IBRX) Director Sells $187,750.00 in Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Christobel Selecky also recently made the following trade(s):

• On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00.

ImmunityBio Stock Performance

Shares of NASDAQ IBRX opened at $6.45 on Friday. The firm has a 50 day moving average price of $2.74 and a two-hundred day moving average price of $2.58. The stock has a market cap of $6.35 billion, a P/E ratio of -15.73 and a beta of 0.03. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $8.28.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million. Analysts predict that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock worth $68,032,000 after acquiring an additional 5,837,898 shares in the last quarter. Armistice Capital LLC bought a new position in shares of ImmunityBio during the 2nd quarter worth about $20,497,000. Heights Capital Management Inc. bought a new position in shares of ImmunityBio during the 3rd quarter worth about $16,152,000. Geode Capital Management LLC grew its stake in shares of ImmunityBio by 34.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock valued at $15,254,000 after buying an additional 1,487,849 shares during the period. Finally, Woodline Partners LP increased its position in ImmunityBio by 53.7% in the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock valued at $13,032,000 after buying an additional 1,851,854 shares in the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

IBRX has been the topic of a number of recent analyst reports. Piper Sandler lifted their price objective on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group lifted their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, BTIG Research boosted their target price on shares of ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a report on Thursday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.